Saeeduddin E Ahmed

US Patent:

6703389, Mar 9, 2004

Filed:

Dec 14, 2001

Appl. No.:

10/020261

Inventors:

Erik H. F. Wong - Portage MI
Saeeduddin Ahmed - Indianapolis IN
Robert C. Marshall - Mattawan MI
Robert McArthur - Kalamazoo MI
Duncan P. Taylor - Kalamazoo MI
Lars Birgerson - Martinsville NJ
Pasquale Cetera - Annandale NJ

Assignee:

Pharmacia Upjohn Company - Kalamazoo MI

International Classification:

A61K 31535

US Classification:

5142392, 5142385

Abstract:

Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (K )/norepinephrine (K ) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

US Patent:

7241762, Jul 10, 2007

Filed:

Feb 7, 2006

Appl. No.:

11/349022

Inventors:

Erik H. F. Wong - Portage MI, US
Saeeduddin Ahmed - Plainfield IN, US
Robert C. Marshall - Mattawan MI, US
Robert McArthur - Kalamazoo MI, US
Duncan P. Taylor - Kalamazoo MI, US

Assignee:

Pharmacia & Upjohn Company - Kalamazoo MI

International Classification:

A61K 35/535

US Classification:

5142392, 5142388

Abstract:

Disclosed herein are methods of treating an individual suffering from peripheral neuropathy. The methods generally include administration of a therapeutic amount of racemic reboxetine, or a pharmaceutically acceptable salt thereof, to the individual.

US Patent:

7276503, Oct 2, 2007

Filed:

Feb 7, 2006

Appl. No.:

11/349373

Inventors:

Erik H. F. Wong - Portage MI, US
Saeeduddin Ahmed - Plainfield IN, US
Robert C. Marshall - Mattawan MI, US
Robert McArthur - Kalamazoo MI, US
Duncan P. Taylor - Kalamazoo MI, US

Assignee:

Pharmacia & Upjohn Company - Kalamazoo MI

International Classification:

A61K 35/535

US Classification:

5142392

Abstract:

Disclosed herein are methods of treating an individual suffering from, chronic fatigue syndrome. The methods generally include administration of a therapeutic amount of optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof, to the individual. Embodiments of these methods can diminish adverse side effects.

US Patent:

7317011, Jan 8, 2008

Filed:

Jan 16, 2004

Appl. No.:

10/758864

Inventors:

Erik H. F. Wong - Portage MI, US
Saeeduddin Ahmed - Plainfield IN, US
Robert Clyde Marshall - Mattawan MI, US
Robert McArthur - Kalamazoo MI, US
Duncan P. Taylor - Kalamazoo MI, US

Assignee:

Pharmacia & Upjohn - Kalamazoo MI

International Classification:

A61K 31/535
A61K 31/537

US Classification:

5142392, 5142388

Abstract:

Disclosed herein are methods of treating an individual suffering from peripheral neuropathy. The methods generally include administration of a therapeutic amount of optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof. Embodiments of these methods can diminish adverse side effects.

US Patent:

7338953, Mar 4, 2008

Filed:

Feb 7, 2006

Appl. No.:

11/349331

Inventors:

Erik H. F. Wong - Portage MI, US
Saeeduddin Ahmed - Plainfield IN, US
Robert C. Marshall - Mattawan MI, US
Robert McArthur - Kalamazoo MI, US
Duncan P. Taylor - Kalamazoo MI, US
Lars Birgerson - Martinsville NJ, US

Assignee:

Pharmacia & Upjohn Company - Kalamazoo MI

International Classification:

A61K 35/535

US Classification:

5142392, 5142388

Abstract:

Disclosed herein are methods of treating an individual suffering from, chronic fatigue syndrome. The methods generally include administration of a therapeutic amount of racemic reboxetine, or a pharmaceutically acceptable salt thereof, to the individual.

US Patent:

20020107249, Aug 8, 2002

Filed:

Jan 23, 2002

Appl. No.:

10/055663

Inventors:

Erik Wong - Portage MI, US
Saeeduddin Ahmed - Plainfield IN, US
Robert Marshall - Mattawan MI, US
Robert McArthur - Basel, CH
Duncan Taylor - Kalamazoo MI, US
Lars Birgerson - Martinsville NJ, US

Assignee:

Pharmacia & Upjohn Company

International Classification:

A61K031/5377

US Classification:

514/238500

Abstract:

Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (K,)/norepinephrine (K) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

US Patent:

20020128173, Sep 12, 2002

Filed:

Jan 4, 2002

Appl. No.:

10/099334

Inventors:

Erik Wong - Portage MI, US
Saeeduddin Ahmed - Indianapolis IN, US
Robert Marshall - Mattawan MI, US
Robert McArthur - Kalamazoo MI, US
Duncan Taylor - Kalamazoo MI, US
Lars Birgerson - Martinsville NJ, US
Pasquale Cetera - Annandale NJ, US

Assignee:

Pharmacia & Upjohn Company

International Classification:

A61K031/00

US Classification:

514/001000

Abstract:

Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (K)/norepinephrine (K) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.

US Patent:

20030040464, Feb 27, 2003

Filed:

Sep 26, 2002

Appl. No.:

10/255450

Inventors:

Erik Wong - Portage MI, US
Saeeduddin Ahmed - Portage MI, US
Robert Marshall - Mattawan MI, US
Robert McArthur - Kalamazoo MI, US
Duncan Taylor - Kalamazoo MI, US
Lars Birgerson - Martinsville NJ, US
Pasquale Cetera - Annandale NJ, US

Assignee:

Pharmacia & Upjohn Company

International Classification:

A61K031/00

US Classification:

514/001000, 514/419000

Abstract:

Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (K)/norepinephrine (K) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.